Gender Effects in Pharmacokinetics and Pharmacodynamics

Drugs

Volumn 50, Issue 2, 1995, Pages 222-239

  Harris, Robert Z ^a,b   Benet, Leslie Z ^a   Schwartz, Janice B ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CLOFIBRATE; CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PHENAZONE; PRAVASTATIN; SEROTONIN UPTAKE INHIBITOR; SUFENTANIL; THEOPHYLLINE; TIRILAZAD; TRAZODONE; UNINDEXED DRUG;

BODY COMPOSITION; CONTRACEPTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TOXICITY; ENZYME ACTIVITY; ETHNOLOGY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LIVER METABOLISM; MALE; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PREGNANCY; REVIEW; SEX DIFFERENCE; URINARY EXCRETION;

ABSORPTION; BODY COMPOSITION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMAN; LIVER; MALE; MENSTRUAL CYCLE; PHARMACOKINETICS; PREGNANCY; PROTEIN BINDING; SEX CHARACTERISTICS; SEX FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029128720     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550020-00003     Document Type: Review

References (170)

1. Women in clinical drug trials: an update
2. Underrepresentation of women in clinical drug trials
3. Sex-related differences in drug disposition in man
4. Influence of age on the pharmacokinetics of alfentanil
5. Aging and alfentanil disposition in healthy volunteers and surgical patients
6. Disposition of alprazolam in human volunteers: differences between genders
7. Alprazolam kinetics in the elderly
8. Influence of menstrual cycle and gender on alprazolam pharmacokinetics
9. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol
10. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition
11. Imipramine and desipramine disposition in the elderly
12. Diazepam kinetics in relation to age and sex
13. Diazepam disposition determinants
14. Age- and gender-related differences in diazepam pharmacokinetics
15. Effect of age and sex on lorazepam protein binding
16. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans
17. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics
18. Effect of age, gender, and obesity on midazolam kinetics
19. Influence of sex, menstrual cycle, and oral contraceptives on the disposition of nitrazepam
20. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers
21. Oxazepam kinetics: effects of age and sex
22. Effect of age and gender on disposition of temazepam
23. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables
24. Influence of sex and oral contraceptive steroids on paracetamol metabolism
25. Comparative pharmacokinetics of paracetamol in men and women considering follicular and luteal phases
26. Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal
27. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events
28. The pharmacokinetic profile of nimesulide in healthy volunteers
29. Effects of age and sex on piroxicam disposition
30. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites
31. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin
32. Salicylate metabolism: effects of age and sex in adults
33. Effects of age and gender on pharmacokinetics of cefepime
34. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects
35. Effect of age and gender on the activity of human hepatic CYP3A
36. Intersubject and dose-related variability after intravenous administration of erythromycin
37. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
38. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimes
39. Biologic determinants of propranolol disposition: results from 1308 patients in the beta-blocker heart attack trial
40. Age and gender influence the stereoslective pharmacokinetics of propranolol
41. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics
42. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
43. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients
44. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics
45. Alterations in prednisolone disposition as a result of time of administration, gender and dose
46. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine
47. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination
48. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance
49. Influence of sex and age on fluorouracil clearance
50. Pharmacokinetics of pravastatin in elderly versus young men and women
51. Sex-related differences in theophylline pharmacokinetics
52. Effect of age and gender on tirilazad pharmacokinetics in humans
53. Gender-related differences in xenobiotic metabolism
54. The use of sodium amytal in the production of anesthesia in the rat
55. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity
56. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly
57. Clinical pharmacokinetics of drugs in obesity
58. Trazodone kinetics: effect of age, gender, and obesity
59. Pharmacokinetics of sufentanil in obese patients
60. Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers
61. Desmethyl-diazepam kinetics in the elderly after oral prazepam
62. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam
63. Hypnotics and sedatives: ethanol
64. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner
65. Effects of age and sex on human drug metabolism
66. The human hepatic cytochromes P450 involved in drug metabolism
67. Identification of an inducible form of cytochrome P-450 in human liver
68. Noninvasive tests of CYP3A enzymes
69. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population
70. The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers
71. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
72. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases
73. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes
74. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation
75. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data
76. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephytoin oxidation polymorphisms
77. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/ debrisoquine oxidation polymorphism
78. Propranolol metabolism in normal subjects: association with sex steroid hormones
79. Pathway-selective sex differences in the metabolic clerance of propanolol in human subjects
80. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron
81. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine
82. Genetic polymorphism of S-mephenytoin hydroxylation
83. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs
84. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities
85. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expressions of single cytochrome P450 isoforms
86. The effect of sex and cardiac failure on the pharmacokinetics of a slow-releace theophylline formulation in the elderly
87. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism
88. Metabolism of digoxin, digitoxosides and digoxigenin in human hepatocytes and liver microsomes
89. Obesity, sex, and acetaminophen disposition
90. Acetaminophen kinetics in the elderly
91. Absorption and distribution of ibuprofen in the elderly
92. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites
93. Effects of age and sex on glomerular filtration rate measured by 51 Cr-EDTA
94. Effect of age and sex on the plasma binding of acidic and basic drugs
95. Sex-related differences in the plasma protein binding of lignocaine and diazepam
96. Inter- and intra-subject variation in diazepam free fraction
97. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives
98. Imipramine serum protein binding in healthy subjects
99. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication
100. Gender-related differences in gastric emptying
101. Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism
102. First-pass metabolism of cyclosporin by the gut
103. Identification and localization of cytochromes P450 in gut
104. Route of administration and sex differences in the pharmacokinetics of asprin, administered as its lysine salt
105. Effects of age and sex on copper absorption, biological half-life, and status in humans
106. Blood flow in muscle groups and drug absorption
107. Estimating the dosage of ribavirin aerosol according to age and other variables
108. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women
109. Pimozide in the treatment of newly admitted schizophrenic patients
110. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation
111. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics
112. Sex differences in bipolar affective disorder: neuroleptic dosage variance
113. Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature. Part II
114. Forms of atypical depression and their response to antidepressant drugs
115. Seasonal variations in binding of 3H-paroxetine to blood platelets in healthy volunteers: indications for gender difference
116. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans
117. Coronary disease: are there gender differences?
118. Hypertension in women: what is really known?
119. Hypertension in women: differences and implications
120. Differences in men and women in cornary artery disease, systemic hypertension and their treatment [editorial]
121. Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium
122. Clinical trials and transethnic pharmacology
123. Factors influencing the pharmacokinetics of cyclosporine in man
124. Postmenopausal hormone replacement therapy and cardiovascular risk reduction: a review
125. Age-related changes in the pharmacodynamics of intravenous glyceryl trinitrate
126. Progestin replacement in the menopause: effects on the endometrium and serum lipids
127. Hormone replacement therapy for prevention and treatment of osteoporosis
128. Supplemental estrogen replacement
129. Hepatic drug metabolism and aging
130. Sex, age and alfentanil pharmacokinetics [letter]
131. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance
132. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens
133. Potentiation of the biologic effect of administered cortisol by estrogen treatment
134. Enhancement of the anti-inflamatory action of hydrocortisone by estrogen
135. Evidence for estrogen receptor-linked calcium transport in the intestine
136. 3 in oophorectomized women
137. Menopause: pharmacodynamics and pharmacokinetics
138. Influence of oral contraceptives on drug therapy
139. Interactions with oral contraceptives
140. Oral contraceptive drug interactions: important considerations
141. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs
142. Pharmacokinetic drug interactions with oral contraceptives
143. Rifampin, oral contraceptives and pregnancy
144. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids
145. The effect of antibiotics on the efficacy of oral contraceptives
146. Factors affecting the enterohepatic circulation of oral contraceptive steroids
147. Self catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates
148. Inter- and intra-individual variation in the metabolism of methaqualone in man after a single oral dose
149. Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics
150. Menstrual cycle effects on caffeine elimination in the human female
151. Phenytoin pharmacokinetics in catmenial epilepsy
152. N-Demethylation of ethylmorphine in pregnant and non-pregnant women and in men: an evaluation of the effects of sex steroids
153. Antipyrine metabolism during the menstrual cycle
154. Serum phenytoin, phenobarbital, carbamazepine, albumin and plasma estradiol progesterone concentrations during the menstrual cycle in women with epilepsy
155. Does the time of the month affect the function of the gut?
156. Starch malabsorption and stool excretion are influenced by the menstrual cycle in women consuming low-fibre western diets
157. Alcohol effects in women during the menstrual cycle
158. Sex differences in absorption kinetics of sodium salicylate
159. Drug therapy during pregnancy and lactation
160. Pregnancy and epilepsy
161. Anticonvulsants in pregnancy
162. Disposition of carbamazepine and phenytoin in pregnancy
163. Pregnancy-induced changes in drug metabolism in epileptic women
164. Plasma antiepileptic drug concentrations during pregnancy
165. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding
166. Tricyclic dose requirements across pregnancy
167. The disposition of caffeine during and after pregnancy
168. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women
169. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study